- Home
- UCAR vs ESLA Comparison
UCAR vs ESLA Comparison
Compare UCAR & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCAR | ESLA |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 32.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UCAR | ESLA |
|---|---|---|
| Price | $8.50 | $0.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $8.00 |
| AVG Volume (30 Days) | ★ 151.2K | 26.7K |
| Earning Date | 05-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.59 |
| 52 Week High | $2.78 | $3.15 |
Technical Indicators
Market Signals| Indicator | UCAR | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 95.41 | 31.52 |
| Support Level | $0.95 | N/A |
| Resistance Level | N/A | $0.85 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.51 | -0.00 |
| Stochastic Oscillator | 93.89 | 21.68 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.